INTRODUCTION
============

'RNA repair' is a versatile mechanism to rectify programmed breaks in tRNAs and mRNAs incurred during tRNA processing and under conditions of cellular stress. Examples include virus-mediated tRNA repair to thwart a host antiviral response to bacteriophage infection ([@B1]), splicing of intron-containing tRNAs ([@B2]) and unconventional mRNA splicing during the unfolded protein response ([@B3],[@B4]). In each of these cases, the inciting event is a site-specific endonuclease cleavage of the target RNA to generate a 2′,3′ cyclic phosphate end and a 5′-OH end. Both broken ends must be healed before they can be sealed by an RNA ligase. Healing entails hydrolysis of the 2′,3′ cyclic phosphate to form a 3′-OH and phosphorylation of the 5′-OH to form a 5′-PO~4~.

Two pathways of tRNA repair have been delineated, which proceed through distinct 3′ end-healing steps that result in different products of the RNA ligase reaction ([@B1],[@B2]). The first pathway is catalyzed by the familiar T4 enzymes polynucleotide kinase-phosphatase (Pnkp) and RNA ligase 1 (Rnl1). Pnkp is a bifunctional enzyme that remodels the ends of the broken tRNA by converting the 2′,3′ cyclic phosphate to a 3′-OH, 2′-OH and by phosphorylating the 5′-OH end to form a 5′-PO~4~. Rnl1 then joins the 3′-OH and 5′-PO~4~ RNA ends to form a standard 3′--5′ phosphodiester at the repair junction ([Figure 1](#F1){ref-type="fig"}A) ([@B1]). The second pathway is catalyzed by yeast tRNA ligase (Trl1), a multifunctional enzyme composed of separable healing and sealing domains ([@B5; @B6; @B7; @B8; @B9; @B10]). The healing domain, Trl1(389--827), consists of a cyclic phosphodiesterase (CPD) module that hydrolyzes the 2′,3′ cyclic phosphate of the proximal tRNA half-molecule to a 3′-OH, 2′-PO~4~ and a polynucleotide kinase module that converts the tRNA 5′-OH to a 5′-PO~4~ ([Figure 1](#F1){ref-type="fig"}A). The ligase domain, Trl1(1--388), then joins the healed ends to form a tRNA with a 2′-PO~4~, 3′--5′ phosphodiester at the splice junction. \[The junction 2′-PO~4~ is ultimately removed by a phosphotransferase, Tpt1, that is specific to the yeast tRNA repair pathway ([@B11])\]. Figure 1.Pathway choice in tRNA splicing is dictated by the outcome of 3′ end healing. (**A**) Distinctive phage and yeast pathways of tRNA repair. In phage tRNA restriction-repair, the 2′,3′ cyclic phosphate and 5′-OH ends of the broken tRNA are healed by T4 Pnkp, which completely removes the phosphate at the 3′ end and phosphorylates the 5′ terminus. T4 Rnl1 then seals the 3′-OH and 5′-PO~4~ termini to form a standard 3′--5′ phosphodiester linkage. In yeast tRNA splicing, the ends are healed by Trl1 kinase-CPD domain (389--827), which generate a 3′-OH, 2′-PO~4~ on the proximal tRNA half and a 5′-PO~4~ on the distal half, and then sealed by a Trl1 ligase domain (1--388). The yeast pathway leaves a 2′-PO~4~ at the splice junction. (**B**) Reaction mixtures (10 µl) containing 50 mM Tris-HCl (pH 7.5), 10 mM MgCl~2~, 5 mM DTT, 25 µM ATP, 25 µM GTP, 140 fmol ^32^P-labeled cleaved tRNA and 1 pmol of T4 Rnl1, T4 Pnkp, Trl1(1--388) or Trl1(389--827), where indicated by + over the lanes, were incubated for 30 min at 37°C. The reactions were quenched by adding 10 µl of 95% formamide, 50 mM EDTA. The samples were heated at 95°C for 1 min and then analyzed by electrophoresis through a 15-cm 15% polyacrylamide gel containing 7 M urea in 45 mM Tris-borate, 1 mM EDTA. The products were visualized by autoradiography.

Recent studies highlight a plethora of target-specific endoribonuclease toxins in bacteria ([@B12; @B13; @B14; @B15; @B16; @B17; @B18]) and fungi ([@B19]) and their role in defending the organism against non-self species and viruses. This raises the question of whether RNA repair systems exist in bacterial cells as a means of evading programmed RNA breakage. Our identification of candidate RNA healing and sealing enzymes in several bacterial proteomes ([@B20],[@B21]) suggests an RNA repair capacity, but the scant knowledge of the genetics and ecology of those bacteria provides no clues to what types of RNA damage might be subject to repair. Here, we demonstrate that an enzyme from *Clostridium thermocellum* (*Cth*Pnkp) can catalyze both of the end-healing steps of tRNA splicing *in vitro*. The biochemical pathway of tRNA repair by the *Cth*Pnkp can be reprogrammed by a mutation in the 3′ end-healing domain that yields a 2′-PO~4~ product instead of a 2′-OH.

MATERIALS AND METHODS
=====================

Recombinant T4 and yeast tRNA repair enzymes
--------------------------------------------

His~10~-tagged versions of T4 Rnl1, T4 Pnkp and yeast Trl1(1--388) were produced in *E. coli* and purified from soluble lysates by Ni-agarose chromatography as described previously ([@B8],[@B22],[@B23]). Yeast Trl1(389--827) was produced in *E. coli* as a His-Smt3 fusion and recovered from a soluble extract by Ni-agarose chromatography. The His-Smt3 tag was removed with the Smt3-specific protease Ulp1 and the tag-free Trl1(398--927) protein was recovered in the flow-through fraction during a second round of Ni-agarose chromatography. SDS-PAGE analysis of the enzyme preparations is shown in [Figure 2](#F2){ref-type="fig"}. Figure 2.Purification of recombinant RNA repair enzymes. Aliquots (5 µg) of the indicated recombinant proteins were analyzed by SDS-PAGE. The Coomassie blue-stained gel is shown. The positions and sizes (kDa) of marker polypeptides are indicated on the left.

Recombinant *Cth*Pnkp
---------------------

Wild-type *Cth*Pnkp and mutated or truncated versions of *Cth*Pnkp were produced in *E. coli* as His~10~-tagged fusions and purified from soluble bacterial extracts by Ni-agarose chromatography ([@B24],[@B25]). The 200-mM imidazole eluates were dialyzed against 150 mM NaCl in buffer A (50 mM Tris-HCl, pH 8.0, 10% glycerol, 1 mM EDTA, 1 mM β-mercaptoethanol) and then applied to 1-ml columns of DEAE-Sephacel that had been equilibrated in buffer A. The columns were washed with 5 ml of buffer A and then eluted stepwise with 200 and 500 mM NaCl in buffer A. The *Cth*Pnkp proteins were recovered in the DEAE flow-through, apparently free of contaminating nucleic acids (which were detected in the 0.5 M NaCl eluate). SDS-PAGE analysis of the *Cth*Pnkp preparations is shown in [Figure 2](#F2){ref-type="fig"}.

Synthesis of pre-tRNA *in vitro*
--------------------------------

The intron-containing pre-tRNA is a chimera consisting of the mature tRNA sequence of plant pre-tRNA^Tyr^ plus the intron and anticodon of *Methanocaldococcus* pre-tRNA^Trp^ ([@B26]). This pre-tRNA was generated by *in vitro* transcription of BstN1-cut plasmid pNtY9-T7-M1 by T7 RNA polymerase in the presence of \[α^32^P\]ATP. A reaction mixture (100 µl) containing 80 mM HEPES-KOH (pH 7.5), 24 mM MgCl~2~, 40 mM DTT, 2 mM spermidine, 2.5 mM CTP, UTP and GTP, 0.5 mM \[α-^32^P\]ATP, 5 µg template DNA, 120 units RNAsin (Promega), 0.5 units yeast inorganic pyrophosphatase (Sigma) and 300 units T7 RNA polymerase (New England Biolabs) was incubated for 3 h at 37°C. The labeled pre-tRNA was purified by electrophoresis through an 8% polyacrylamide-urea gel. The pre-tRNA was eluted from an excised gel slice in 650 µl of 10 mM Tris-HCl (pH 8.0), 1 mM EDTA. This procedure yielded 380--420 pmol of pre-tRNA.

Cleavage of the pre-tRNA with archaeal-splicing endonuclease
------------------------------------------------------------

pre-tRNA cleavage reaction mixtures (100 µl) containing 50 mM Tris-HCl (pH 7.5), 100 mM KCl, 10 mM MgCl~2~, 1 mM DTT, 40 µM spermine, 40 pmol \[^32^P\[AMP-labeled pre-tRNA and 1.5 µg *Methanocaldococcus jannaschii* tRNA-splicing endonuclease (produced in *E. coli* as a His~10~ fusion and purified by Ni-agarose chromatography) were incubated for 20 min at 65°C. The RNA products were phenol-extracted, precipitated with ethanol (28--32 pmol of cleaved tRNA recovered), resuspended in 100 µl of 10 mM Tris-HCl (pH 8.0), 1 mM EDTA and stored at −20°C.

RESULTS AND DISCUSSION
======================

Distinct tRNA repair pathways *in vitro*
----------------------------------------

The finding that the essential healing and sealing components of the yeast tRNA-splicing system can be replaced *in vivo* by their bacteriophage analogs ([@B27]) attested to the portability of RNA repair systems from widely distant taxa. However, certain restrictions apply. T4 Pnkp can substitute for the yeast kinase-CPD domain only in tandem with T4 Rnl1 and the yeast ligase domain functions only in tandem with yeast kinase-CPD. Because the kinase modules of the phage and yeast healing enzymes are structurally homologous and the reaction products are identical (a 5′-PO~4~ RNA end), the critical factor appears to be the distinctive 3′-OH, 2′-PO~4~ end configuration generated by yeast CPD versus the 3′-OH, 2′-OH end produced by T4 Pnkp. In other words, the yeast tRNA ligase appears to require the 2′-PO~4~ terminus to seal tRNAs *in vivo*.

To better delineate the specificity of end-healing and end-sealing during tRNA repair/splicing, we exploited an *in vitro* tRNA-splicing system designed by Englert and Beier ([@B26]). The broken tRNA substrate was generated by treating a ^32^P-labeled intron-containing pre-tRNA with a tRNA-splicing endonuclease, which led to quantitative release of a linear 21-nt intron and the formation of two 'half-tRNA' molecules: a 37-nt 5′ fragment and a 39-nt 3′-fragment ([Figure 1](#F1){ref-type="fig"}B). Reaction of the broken RNA with a combination of yeast Trl1(1--388) and Trl1(389--827) resulted in a mature spliced tRNA and the circularization of the intron. Splicing of the tRNA halves and intron circularization were also seen with T4 Rnl1 plus T4 Pnkp. However, the ligase domain of yeast Trl1 was unable to splice the tRNA or circularize the intron when paired with T4 Pnkp ([Figure 1](#F1){ref-type="fig"}B). This *in vitro* observation echoes precisely the inability of Trl1(1--388) to function together with T4 Pnkp *in vivo*. This incompatibility reflects a requirement for a 3′-OH, 2′-PO~4~ terminus in order for the ligase component of Trl1 to seal the broken RNA ends *in vitro*.

*Clostridium* Pnkp performs the end-healing steps of tRNA repair
----------------------------------------------------------------

*Cth*Pnkp catalyzes the phosphorylation of 5′-OH termini of DNA or RNA polynucleotides and the dephosphorylation of 2′,3′ cyclic phosphate, 2′-phosphate and 3′-phosphate ribonucleotides ([@B21],[@B24],[@B25]). These characteristics are consistent with a role in end healing during RNA or DNA repair. *Cth*Pnkp is an 870-aa polypeptide composed of three catalytic domains: an N-terminal module that resembles the kinase domain of T4 Pnkp, a central phosphoesterase module and a C-terminal module that resembles the adenylyltransferase domain of polynucleotide ligases. The distinctive feature of *Cth*Pnkp *vis a vis* known repair enzymes is that its 3′ end modification component belongs to the binuclear metallophosphoesterase superfamily ([@B24],[@B25]). The salient question is whether *Cth*Pnkp can perform a *bona fide* RNA repair reaction and, if so, to which of the two known repair pathways it adheres. We found that *Cth*Pnkp functioned in tRNA splicing *in vitro* as the sole source of end-healing activity when added in tandem with T4 Rnl1, resulting in the formation of a spliced tRNA product and an intron circle ([Figure 3](#F3){ref-type="fig"}). However, splicing activity was attenuated severely when yeast Trl1(1--388) replaced phage Rnl1 as the source of the RNA sealing activity ([Figure 3](#F3){ref-type="fig"}). We surmise that the predominant outcome of *Cth*Pnkp healing of a tRNA 2′,3′ cyclic phosphate end is not the 3′-OH, 2′-PO~4~ required by yeast tRNA ligase. Figure 3.Wild-type *Cth*Pnkp elects the phage tRNA repair pathway. Reaction mixtures (20 µl) containing 50 mM Tris-acetate (pH 6.5), 5 mM MgCl~2~, 0.5 mM MnCl~2~, 50 µM ATP, 200 fmol radiolabeled cleaved tRNA substrate, either 1 pmol Trl1(1--388) or 1 pmol T4 Rnl1, and *Cth*Pnkp as specified were incubated for 30 min at 37°C. The products were resolved by PAGE and visualized by autoradiography.

Mechanism of 3′ end healing by *Cth*Pnkp
----------------------------------------

To better address how *Cth*Pnkp acts at a 2′,3′ cyclic phosphate end, we compared the release of inorganic phosphate (P~i~) from 2′,3′ cAMP by *Cth*Pnkp alone versus a duplicate sample in which the products were treated with calf intestinal phosphatase (CIP) prior to assay of P~i~ release ([Figure 4](#F4){ref-type="fig"}A). Whereas *Cth*Pnkp converted 16% of the input 2′,3′ cAMP to P~i~, treatment of the reaction product with CIP increased the yield of P~i~ to 90% of the input 2′,3′ cAMP substrate. (Treatment with CIP alone released \<2% of the P~i~ from 2′,3′ cAMP.) These results indicate that a nucleoside 2′,3′ cyclic phosphate is converted by *Cth*Pnkp to a phosphomonoester prior to the release of P~i~. The transient nature of the phosphomonoester intermediate would account for why *Cth*Pnkp-mediated tRNA repair proceeds down the bacteriophage-type pathway. Figure 4.*Cth*Pnkp-H189D opens a 2′,3′ cyclic phosphodiester to form a 2′-phosphomonoester. (**A**) Reaction mixtures (10 µl) containing 50 mM Tris-HCl (pH 7.5), 0.5 mM MnCl~2~, 10 mM 2′,3′ cAMP (Sigma) and either 4 µg wild-type *Cth*Pnkp, 1.4 µg *Cth*Pnkp-H189D or 1 unit CIP (New England Biolabs) where indicated by + were incubated for 30 min at 45°C. The reactions were quenched by adding 1 µl of 0.5 M EDTA. Phosphate release was measured colorimetrically using the Malachite green reagent (BIOMOL Research Laboratories). (**B**) Reaction mixtures containing (per 10 µl) 50 mM Tris-HCl (pH 8.0), 0.5 mM MnCl~2~, 10 mM 2′,3′ cAMP and either 1.4 µg of *Cth*Pnkp-H189D and 1 U of CIP (closed circle), 1.4 µg of *Cth*Pnkp-H189D alone (closed triangle) or 1 U of CIP alone (open circle) were incubated at 45°C. Aliquots (10 µl) were withdrawn at the times specified and quenched immediately with EDTA. Phosphate release is plotted as a function of time. (**C**) A reaction mixture containing (per 10 µl) 50 mM Tris-HCl (pH 8.0), 0.5 mM MnCl~2~, 10 mM 2′,3′ cAMP and 1.4 µg of *Cth*Pnkp-H189D was incubated at 45°C. Samples (10 µl) were withdrawn at the times specified and quenched immediately with EDTA. Aliquots (1 µl) of each sample were applied to a cellulose-F TLC plate (EMD Chemicals). Markers 2′AMP, 3′AMP and 2′,3′ cAMP (5 nmol each) were spotted in lane M. The TLC plate was developed with buffer containing saturated ammonium sulfate:3 M sodium acetate:isopropanol (80:6:2), in which the order of migration away from the origin (R~f~) is 2′,3′ cyclic phosphate \<3′-phosphate \<2′-phosphate ([@B28],[@B29]). The nucleotides were visualized by photography under UV light. All species on the TLC plate that were detected by UV are shown in the photograph.

Studies of the catalytic mechanism of the *Cth*Pnkp phosphoesterase have shown it to be plastic, insofar as certain mutations in the active site alter the reaction outcome ([@B25]). In particular, an H189D change abolished the phosphomonoesterase activity with *p*-nitrophenylphosphate as a substrate, without affecting the phosphodiesterase activity with bis-*p*-nitrophenylphosphate ([@B25]). Here, we find that *Cth*Pnkp-H189D failed to release inorganic phosphate from 2′,3′ cAMP, while converting 88% of the input 2′,3′ cAMP to a monoester that was hydrolyzed by CIP ([Figure 4](#F4){ref-type="fig"}A). The reaction in substrate excess proceeded to near completion with apparent pseudo-first-order kinetics ([Figure 4](#F4){ref-type="fig"}B) at an initial rate of 20 s^−1^. The transformation of *Cth*Pnkp into a CPD-only end-healing enzyme by the H189D mutation allowed us to probe the outcome of the CPD reaction, by performing TLC analysis of the reaction mixture as a function of reaction time in the presence of *Cth*Pnkp only (no CIP). This revealed a single-step conversion of 2′,3′ cAMP to a faster moving product that comigrated with 2′ AMP ([Figure 4](#F4){ref-type="fig"}C). We infer that a 2′ phosphomonoester is the relevant intermediate in tRNA end healing by wild-type *Cth*Pnkp.

The H189D change alters the pathway of tRNA repair
--------------------------------------------------

Testing the activity of *Cth*Pnkp-H189D in tRNA splicing revealed that its RNA repair specificity had been transformed so that its healing activity was now channeled through the yeast-type repair pathway. H189D exhibited a gain of function in working with the yeast ligase to perform both tRNA splicing and intron circularization ([Figure 5](#F5){ref-type="fig"}). *Cth*Pnkp-H189D had no repair activity in the absence of Trl1(1--388) (not shown). Moreover, a truncated version of H189D (aa 1--472) containing just the kinase and phosphoesterase modules retained full activity in tRNA splicing in combination with Trl1(1--388) ([Figure 5](#F5){ref-type="fig"}). Thus, the C-terminal adenylyltransferase domain of *Cth*Pnkp was noncontributory to the observed tRNA repair activity. We introduced into the H189D-healing domain a second mutation in the ATP-binding motif of the polynucleotide kinase module. The K21A change abolished 5′ kinase activity, without impacting the cyclic phosphoesterase function ([Figure 6](#F6){ref-type="fig"}). The K21A-H189D double mutant was inert in tRNA repair ([Figure 5](#F5){ref-type="fig"}), proving that the bacterial enzyme is the source of the 5′ end-healing function for tRNA splicing *in vitro*. Figure 5.The H189D change redirects *Cth*Pnkp down the yeast tRNA-splicing pathway. Reaction mixtures (20 µl) containing 50 mM Tris-acetate (pH 6.5), 0.5 mM MnCl~2~, 50 µM ATP, 5 mM MgCl~2~, 200 fmol of cleaved tRNA substrate, 1 pmol Trl1(1--388) and wild-type *Cth*Pnkp, or mutated versions as specified were incubated for 30 min at 37°C. The products were resolved by PAGE and visualized by autoradiography. Figure 6.The K21A mutation of *Cth*Pnkp abolishes the 5′ kinase activity without affecting the 2′,3′ phosphodiesterase. (**A**) Phosphodiesterase reaction mixtures (10 µl) containing 50 mM Tris-HCl (pH 7.5), 0.5 mM MnCl~2~, 10 mM 2′,3′ cAMP and either 0.8 µg *Cth*Pnkp(1--472)-H189D, 0.8 µg *Cth*Pnkp(1--472)-K21A-H189D or 1 unit CIP (where indicated by +) were incubated for 30 min at 45°C. Phosphate release was measured by using the Malachite green reagent. (**B**) Polynucleotide kinase reaction mixtures (10 µl) containing 50 mM Tris-acetate (pH 7.0), 5 mM DTT, 100 µM \[γ^32^P\]ATP, 10 µM 5′-OH oligodeoxynucleotide 12-mer 5′-CACTATCGGAAT and *Cth*Pnkp(1--472)-H189D or *Cth*Pnkp(1--472)-K21A-H189D as specified were incubated for 30 min at 45°C. The reactions were quenched with 10 µl of 95% formamide, 50 mM EDTA. The products were analyzed by urea-PAGE and visualized by autoradiography.

CONCLUSIONS
===========

The present study illuminates several aspects of RNA repair: (i) the demonstration of a repair-competent RNA end-healing enzyme encoded by a bacterium (to our knowledge, the first case so documented); (ii) repair pathway choice based on the compatibility of the 3′ end-healing and sealing reaction specificities; and (iii) the ability to reprogram the choice of repair pathway by a single missense mutation in the 3′ end-healing component. These properties suggest that RNA repair enzymes and pathways can quickly evolve (or co-evolve) their specificities to suit a particular biological context, e.g. the CPD reaction chemistry and stringent specificity of yeast Trl1 for a 3′-OH, 2′-PO~4~ terminus ensures avoidance of sealing RNA ends not generated by programmed cleavage events ([@B27]).

Although *Cth*Pnkp is clearly tRNA repair-competent *in vitro*, our initial attempts to replace Trl1(389--827) with *Cth*Pnkp-H189D *in vivo* in yeast were not successful. We suspect that the non-portability of this RNA repair enzyme reflects idiosyncratic aspects of foreign protein expression or localization in budding yeast, rather than any mechanistic deficit, insofar as we were also unable to complement a *Saccharomyces cerevisiae trl1Δ* strain with the Trl1 ortholog from fission yeast *Schizosaccharomyces pombe*.

Based on the detection of *Cth*Pnkp-like proteins with similar size and domain organization in many other bacterial genera (*Bacillus, Helicobacter, Fusobacterium, Herpetosiphon* and *Maricaulis*), we propose that bacterial RNA repair is hiding in plain sight.
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